Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,689 across all filing types
Latest filing 2020-07-30 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
关于召开2020年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2020 second extraordinary general meeting (临时股东大会) of Dirui Medical Technology Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items (notably a related party transaction involving a share transfer agreement), registration methods, and proxy forms. There is no financial data or results reported, nor is it a transcript or presentation. It is not an announcement of voting results but a notice to shareholders about the meeting and how to participate and vote. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings.
2020-07-30 Chinese
第四届董事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from the company regarding the approval of the 2020 semi-annual report and its summary. It states that the board has reviewed and passed the proposal to approve the semi-annual report, and it references the full report being available on an external website. The document itself does not contain the actual financial statements or substantive financial data but is an announcement of the board's approval of the interim report. Given the short length (652 characters) and the nature of the content, this fits the category of a Regulatory Filing (RNS) rather than the Interim/Quarterly Report (IR) itself, as per the 'Menu vs Meal' rule and certification rule.
2020-07-30 Chinese
拟股权转让所涉及的宁波瑞源生物科技有限公司股东全部权益价值项目资产评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an "资产评估报告" (Asset Valuation Report) related to the equity transfer of Ningbo Ruiyuan Biotechnology Co., Ltd., commissioned by Dirui Medical Technology Co., Ltd. It contains detailed valuation of shareholder equity, asset and liability lists, company background, historical equity changes, financial data audited by accounting firms, and valuation methods. The document is lengthy (15,000 characters) and contains substantive financial and valuation data, not merely an announcement or summary. It is not an annual or interim financial report, nor an earnings release or management discussion. It is a formal asset valuation report prepared according to Chinese asset valuation standards, used for equity transfer purposes. This fits best under the category of Audit Report / Information (AR), which includes standalone audit and valuation reports related to accounting and asset valuation, excluding full annual reports. Therefore, the correct classification is AR with high confidence. H1 2020
2020-07-30 Chinese
2020年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "迪瑞医疗科技股份有限公司 2020 年半年度报告全文" which translates to "Dirui Medical Technology Co., Ltd. 2020 Semi-Annual Report Full Text." It explicitly states it is a half-year report for the period January 1, 2020 to June 30, 2020. The content includes detailed financial data, management discussion and analysis, business overview, risk factors, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an annual report (10-K) or a regulatory filing or announcement. The presence of detailed financial statements and analysis confirms it is an Interim / Quarterly Report (IR). H1 2020
2020-07-30 Chinese
关于公司高级管理人员减持股份预披露公告
Director's Dealing Classification · 100% confidence The document is a public announcement regarding the planned reduction of shareholdings by two senior management personnel of the company. It details the names of the individuals, the number of shares they intend to sell, the reasons for the sale, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or detailed financial analysis present. The document is focused on insider share transactions by company executives, which fits the definition of Director's Dealing filings.
2020-07-26 Chinese
公司与安信证券股份有限公司关于公司申请向不特定对象发行可转换公司债券的审核问询函的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to a regulatory inquiry (审核问询函) from the Shenzhen Stock Exchange regarding the company's application to issue convertible bonds to unspecified investors. It contains extensive disclosures about the company's overseas sales, distributor contracts, risks related to international trade friction, COVID-19 impact, intellectual property, and import restrictions. The document includes financial data for multiple years and detailed management explanations and risk disclosures. It is not a full annual or quarterly report but a regulatory response document related to a capital raising activity (issuance of convertible bonds). The document is lengthy (15,000 characters) and contains substantive financial and operational information, not just an announcement or certification. Given the focus on the issuance of convertible bonds and the detailed discussion of related financial and operational matters, the document best fits the category of Capital/Financing Update (CAP).
2020-07-22 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.